PRINCETON, N.J.--(BUSINESS WIRE)--The results of the Patients with REnal impairment and DIabetes undergoing Computed Tomography (PREDICT) study were just published in the American Journal of Roentgenology1 (Am J Roentgenol. 2008;191: 151-157). The PREDICT trial is the largest, prospective, randomized, double-blind comparison of the iso-osmolar iodixanol-320 with the low-osmolar iopamidol-370 in high-risk patients undergoing computed tomography (CT). The PREDICT study found no statistically significant difference between iopamidol-370 and iodixanol-320 in the rate of contrast-induced nephropathy (CIN) in high-risk patients undergoing CT.
